Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.96
CERS's Cash-to-Debt is ranked lower than
66% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CERS: 2.96 )
Ranked among companies with meaningful Cash-to-Debt only.
CERS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.62  Med: 26.98 Max: 14206.57
Current: 2.96
0.62
14206.57
Equity-to-Asset 0.49
CERS's Equity-to-Asset is ranked lower than
71% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CERS: 0.49 )
Ranked among companies with meaningful Equity-to-Asset only.
CERS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.06  Med: 0.67 Max: 0.9
Current: 0.49
0.06
0.9
Piotroski F-Score: 4
Altman Z-Score: -9.36
Beneish M-Score: -2.66
WACC vs ROIC
10.73%
-912.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -160.18
CERS's Operating Margin % is ranked lower than
56% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CERS: -160.18 )
Ranked among companies with meaningful Operating Margin % only.
CERS' s Operating Margin % Range Over the Past 10 Years
Min: -390.85  Med: -127.38 Max: -47.15
Current: -160.18
-390.85
-47.15
Net Margin % -161.29
CERS's Net Margin % is ranked lower than
57% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. CERS: -161.29 )
Ranked among companies with meaningful Net Margin % only.
CERS' s Net Margin % Range Over the Past 10 Years
Min: -410.21  Med: -121.75 Max: -43.38
Current: -161.29
-410.21
-43.38
ROE % -98.01
CERS's ROE % is ranked lower than
77% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CERS: -98.01 )
Ranked among companies with meaningful ROE % only.
CERS' s ROE % Range Over the Past 10 Years
Min: -140.02  Med: -82.23 Max: -56.33
Current: -98.01
-140.02
-56.33
ROA % -58.45
CERS's ROA % is ranked lower than
71% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. CERS: -58.45 )
Ranked among companies with meaningful ROA % only.
CERS' s ROA % Range Over the Past 10 Years
Min: -65.51  Med: -46.82 Max: -33.76
Current: -58.45
-65.51
-33.76
ROC (Joel Greenblatt) % -805.04
CERS's ROC (Joel Greenblatt) % is ranked lower than
59% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. CERS: -805.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CERS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2927.5  Med: -922.65 Max: -501.14
Current: -805.04
-2927.5
-501.14
3-Year Revenue Growth Rate -13.00
CERS's 3-Year Revenue Growth Rate is ranked lower than
69% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CERS: -13.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CERS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -44.5  Med: 0.8 Max: 52.4
Current: -13
-44.5
52.4
3-Year EBITDA Growth Rate -2.60
CERS's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CERS: -2.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CERS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -52.8  Med: 6.1 Max: 127.1
Current: -2.6
-52.8
127.1
3-Year EPS without NRI Growth Rate -1.10
CERS's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CERS: -1.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CERS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 2.3 Max: 22.7
Current: -1.1
-30.1
22.7
GuruFocus has detected 1 Warning Sign with Cerus Corp $CERS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CERS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CERS Guru Trades in Q2 2016

Ron Baron 81,000 sh (+28.57%)
Jim Simons 21,400 sh (+15.05%)
PRIMECAP Management 7,800,000 sh (unchged)
Chuck Royce 248,000 sh (-7.46%)
» More
Q3 2016

CERS Guru Trades in Q3 2016

Paul Tudor Jones 12,900 sh (New)
Ron Baron 103,500 sh (+27.78%)
Chuck Royce 248,000 sh (unchged)
PRIMECAP Management 7,800,000 sh (unchged)
Jim Simons Sold Out
» More
Q4 2016

CERS Guru Trades in Q4 2016

Jim Simons 82,000 sh (New)
Ron Baron 282,500 sh (+172.95%)
Chuck Royce 248,000 sh (unchged)
PRIMECAP Management 7,800,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q1 2017

CERS Guru Trades in Q1 2017

Steven Cohen 410,800 sh (New)
Ron Baron 464,300 sh (+64.35%)
Jim Simons 92,500 sh (+12.80%)
Chuck Royce 248,000 sh (unchged)
PRIMECAP Management 7,800,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CERS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2834
Compare:NAS:OVID, OTCPK:BBLG, NAS:CBAY, NAS:CEMP, NAS:ALBO, OTCPK:RCAR, NAS:CKPT, NAS:CMRX, NAS:PTGX, NAS:SBBP, NAS:NLNK, OTCPK:TYMI, NAS:PPHM, NAS:FBIO, NAS:PIRS, NAS:CLSD, NAS:KURA, NAS:CASC, OTCPK:SIGA, NAS:IMDZ » details
Traded in other countries:CU2.Germany,
Headquarter Location:USA
Cerus Corp is a biomedical products company. It is engaged in developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Cerus Corp was incorporated in California on September 19, 1991 and reincorporated in Delaware in 1996. It is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received CE marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, or CIS, the Middle East and selected countries in other regions around the world. The Company sells both the platelet and plasma systems using its direct sales force and through distributors. Company continue to use, third parties to manufacture and supply the devices, disposable kits and inactivation compounds that make up the INTERCEPT Blood System for use in clinical trials and for commercialization. The Company owns approximately 12 issued or allowed United States patents and approximately 87 issued or allowed foreign patents related to the INTERCEPT Blood System. The market for the INTERCEPT Blood System is subjected by a relatively small number of blood collection organizations. Many of these organizations are national blood transfusion services or Red Cross organizations who collect, store and distribute virtually all of their respective nations' blood and blood component supplies. The European markets for its products are in Germany, France, and England. The Company and its products are comprehensively regulated in the United States by the FDA and, in some instances, by state and local governments, and by comparable governmental authorities in other countries.

Guru Investment Theses on Cerus Corp

Baron Funds Comments on Cerus Corp - Jan 20, 2017

Cerus Corporation (NASDAQ:CERS) has an FDA and EU approved device that inactivates pathogens such as viruses and bacteria in donated blood. Current regulatory approvals cover use of the Cerus device for platelets and plasma from donated blood (an $800 million worldwide, and $350 million U.S. market opportunity, for which Cerus has signed up over 80% of all U.S. blood centers). If additional approvals for usage with red blood cell (RBC) components are obtained, Cerus will add an estimated $2.5 billion in market opportunity ($1 billion in the U.S., in the same blood centers), for which there is no current competition. Shares slipped in the fourth quarter as the company slightly extended its timeline (by what we estimate might be one to two quarters) to get the RBC product to market. We believe Cerus is targeting EU approval for RBC in early 2018, and we believe that U.S. approval could be obtained for RBC in 2019. We believe growth prospects for Cerus are significant for 2017 and beyond.



From Baron Discovery Fund's fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Cerus Corp - Feb 25, 2016

Cerus Corporation (NASDAQ:CERS) is a leading provider of medical equipment to the blood banking industry. Its equipment performs pathogen inactivation (PI) on donated blood, preventing infections via transfused blood caused by viruses and bacteria in donated units. Cerus gained significantly in the fourth quarter as it started to gain contracts with a significant number of U.S. blood centers for PI in platelets and plasma. We believe that Cerus has what is likely to be an insurmountable lead in the U.S., and market leading E.U. position for its products. We should see substantial growth for years to come as we expect these markets, which are currently worth about $800 million (for platelets and plasma), could grow to over $3 billion when PI is extended to red blood cell inactivation over the next three to four years.



From Baron Discover Fund's fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Cerus Corp

Cerus Corporation (Nasdaq: CERS) to Ring the Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco
Baron Funds Comments on Cerus Corp Guru stock highlight
Cerus Corporation (NASDAQ:CERS) has an FDA and EU approved device that inactivates pathogens such as viruses and bacteria in donated blood. Current regulatory approvals cover use of the Cerus device for platelets and plasma from donated blood (an $800 million worldwide, and $350 million U.S. market opportunity, for which Cerus has signed up over 80% of all U.S. blood centers). If additional approvals for usage with red blood cell (RBC) components are obtained, Cerus will add an estimated $2.5 billion in market opportunity ($1 billion in the U.S., in the same blood centers), for which there is no current competition. Shares slipped in the fourth quarter as the company slightly extended its timeline (by what we estimate might be one to two quarters) to get the RBC product to market. We believe Cerus is targeting EU approval for RBC in early 2018, and we believe that U.S. approval could be obtained for RBC in 2019. We believe growth prospects for Cerus are significant for 2017 and beyond. Read more...

Ratios

vs
industry
vs
history
PB Ratio 5.46
CERS's PB Ratio is ranked lower than
69% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CERS: 5.46 )
Ranked among companies with meaningful PB Ratio only.
CERS' s PB Ratio Range Over the Past 10 Years
Min: 0.81  Med: 6.74 Max: 55
Current: 5.46
0.81
55
PS Ratio 5.56
CERS's PS Ratio is ranked higher than
64% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CERS: 5.56 )
Ranked among companies with meaningful PS Ratio only.
CERS' s PS Ratio Range Over the Past 10 Years
Min: 1.22  Med: 7.38 Max: 21.24
Current: 5.56
1.22
21.24
EV-to-EBIT -3.04
CERS's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CERS: -3.04 )
Ranked among companies with meaningful EV-to-EBIT only.
CERS' s EV-to-EBIT Range Over the Past 10 Years
Min: -77.8  Med: -7.7 Max: -0.2
Current: -3.04
-77.8
-0.2
EV-to-EBITDA -3.13
CERS's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CERS: -3.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
CERS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -111.9  Med: -8 Max: -0.2
Current: -3.13
-111.9
-0.2
Current Ratio 2.86
CERS's Current Ratio is ranked lower than
62% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CERS: 2.86 )
Ranked among companies with meaningful Current Ratio only.
CERS' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 3.98 Max: 9.96
Current: 2.86
1.03
9.96
Quick Ratio 2.37
CERS's Quick Ratio is ranked lower than
65% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CERS: 2.37 )
Ranked among companies with meaningful Quick Ratio only.
CERS' s Quick Ratio Range Over the Past 10 Years
Min: 1.03  Med: 3.65 Max: 9.96
Current: 2.37
1.03
9.96
Days Inventory 225.81
CERS's Days Inventory is ranked lower than
76% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. CERS: 225.81 )
Ranked among companies with meaningful Days Inventory only.
CERS' s Days Inventory Range Over the Past 10 Years
Min: 122.1  Med: 208.46 Max: 343.01
Current: 225.81
122.1
343.01
Days Sales Outstanding 50.85
CERS's Days Sales Outstanding is ranked higher than
62% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CERS: 50.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
CERS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.2  Med: 68.27 Max: 256.86
Current: 50.85
44.2
256.86
Days Payable 162.63
CERS's Days Payable is ranked higher than
79% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. CERS: 162.63 )
Ranked among companies with meaningful Days Payable only.
CERS' s Days Payable Range Over the Past 10 Years
Min: 81.15  Med: 127.78 Max: 705.63
Current: 162.63
81.15
705.63

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.90
CERS's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CERS: -12.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CERS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.8  Med: -13.3 Max: -6.8
Current: -12.9
-20.8
-6.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 21.80
CERS's Price-to-Net-Cash is ranked lower than
83% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. CERS: 21.80 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CERS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.88  Med: 7.04 Max: 103.13
Current: 21.8
1.88
103.13
Price-to-Net-Current-Asset-Value 7.03
CERS's Price-to-Net-Current-Asset-Value is ranked lower than
54% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CERS: 7.03 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CERS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.17  Med: 7.52 Max: 317.86
Current: 7.03
1.17
317.86
Price-to-Tangible-Book 5.74
CERS's Price-to-Tangible-Book is ranked lower than
61% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CERS: 5.74 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CERS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.92  Med: 7.01 Max: 250
Current: 5.74
0.92
250
Price-to-Median-PS-Value 0.76
CERS's Price-to-Median-PS-Value is ranked higher than
59% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CERS: 0.76 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CERS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 1.29 Max: 70.99
Current: 0.76
0.19
70.99
Earnings Yield (Greenblatt) % -32.59
CERS's Earnings Yield (Greenblatt) % is ranked lower than
78% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CERS: -32.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CERS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -412  Med: -13.1 Max: -1.3
Current: -32.59
-412
-1.3

More Statistics

Revenue (TTM) (Mil) $40.08
EPS (TTM) $ -0.63
Beta1.39
Short Percentage of Float12.68%
52-Week Range $1.93 - 7.64
Shares Outstanding (Mil)104.86

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.70 -0.55
EPS without NRI ($) -0.70 -0.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CERS

Headlines

Articles On GuruFocus.com
Cerus Corporation (Nasdaq: CERS) to Ring the Nasdaq Stock Market Closing Bell Remotely from the Nasd Apr 07 2017 
Baron Funds Comments on Cerus Corp Jan 20 2017 
Baron Funds Comments on Cerus Corp Feb 25 2016 
Cerus Corp. Reports Operating Results (10-K) Mar 16 2011 
Cerus Corp. Reports Operating Results (10-Q) Aug 16 2010 
Cerus Corp. Reports Operating Results (10-Q) May 12 2010 
Cerus Corp. Reports Operating Results (10-Q) Nov 06 2009 

More From Other Websites
Cerus to Release Second Quarter 2017 Results on August 3, 2017 Jul 21 2017
ETFs with exposure to Cerus Corp. : July 11, 2017 Jul 11 2017
INTERCEPT Blood System Highlighted at the International Society of Blood Transfusion (ISBT) Jun 21 2017
Today's Research Reports on Stocks to Watch: Calithera Biosciences and Cerus Corporation Jun 08 2017
Here's Why Cerus Corporation Rose as Much as 17.4% Today Jun 07 2017
Cerus Provides Update on U.S. Platelet Additive Solution (PAS) Supply Jun 07 2017
Today's Research Reports on Stocks to Watch: Teva and Cerus Corporation May 24 2017
Here's Why Cerus Corporation Stock Is Tanking Today May 23 2017
Cerus stock plunges 16% after news of temporary impact to US blood centers, revenue warning May 23 2017
Biotech Movers: Cerus, Alexion, NantKwest May 23 2017
Cerus Provides U.S. Business Update May 23 2017
ETFs with exposure to Cerus Corp. : May 22, 2017 May 22 2017
Class Of 1997: 2 Decades After Their IPOs, Where Are These Companies Now? May 16 2017
First Patient Transfused in Cerus’ Phase III RedeS Study Evaluating Safety and Efficacy of the... May 15 2017
Cerus Corp. :CERS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 May 10 2017
Cerus Announces Exercise of Additional BARDA Contract Options Totaling $46.6 million to Support... May 09 2017
Edited Transcript of CERS earnings conference call or presentation 3-May-17 8:15pm GMT May 06 2017
Here's Why Cerus Corporation Dropped as Much as 33.2% This Morning May 04 2017
Cerus Corp. breached its 50 day moving average in a Bearish Manner : CERS-US : May 4, 2017 May 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}